IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
223 hedge funds and large institutions have $3.58B invested in IVERIC bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 35 closing their positions.
20% more call options, than puts
Call options by funds: $59.3M | Put options by funds: $49.2M
15% more capital invested
Capital invested by funds: $3.12B → $3.58B (+$468M)
9% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 78
3% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 35
1% less funds holding
Funds holding: 225 → 223 (-2)
21% less funds holding in top 10
Funds holding in top 10: 19 → 15 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$76.8M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$59.4M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$50.4M |
| 4 |
Holocene Advisors
New York
|
+$43.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$43.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$63.5M |
| 2 |
DM
Deerfield Management
New York
|
-$42M |
| 3 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$32.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$30.2M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$27.4M |
ISEE Hedge Fund Activity: Q1 2023 in Review
223 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q1 2023, worth a combined $3.58B — up 15% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ISEE positions and 35 closed out — a net gain of 1 holder — while 85 added to existing stakes and 78 trimmed.
The largest buyer was Vanguard Group, adding an estimated $76.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $63.5M sold.
- 223 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q1 2023, down from 225 in Q4 2022.
- Funds reported $3.58B of IVERIC bio, Inc. Common Stock stock for Q1 2023, up 15% quarter-over-quarter.
- 36 funds opened new IVERIC bio, Inc. Common Stock positions in Q1 2023 and 35 closed out, a net change of +1 holder.
- The largest IVERIC bio, Inc. Common Stock buyer in Q1 2023 was Vanguard Group, an estimated $76.8M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q1 2023 was Point72 Asset Management, an estimated $63.5M sold.
Based on aggregated 13F filings for Q1 2023.